Rupert Langer


Affiliation: Klinikum rechts der Isar
Country: Germany


  1. Langer R, Feith M, Siewert J, Wester H, Hoefler H. Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus. BMC Cancer. 2008;8:70 pubmed publisher
  2. Langer R, Ott K, Specht K, Becker K, Lordick F, Burian M, et al. Protein expression profiling in esophageal adenocarcinoma patients indicates association of heat-shock protein 27 expression and chemotherapy response. Clin Cancer Res. 2008;14:8279-87 pubmed publisher
    ..Moreover, the potential of HSPs and GRPs as biomarkers of chemotherapy response warrants further validation. ..
  3. Langer R, Becker K, Feith M, Friess H, Hofler H, Keller G. Genetic aberrations in primary esophageal melanomas: molecular analysis of c-KIT, PDGFR, KRAS, NRAS and BRAF in a series of 10 cases. Mod Pathol. 2011;24:495-501 pubmed publisher
    ..We conclude that molecular analysis can identify targets for a specific therapy such as tyrosin kinase inhibitors as additional treatment option in these highly malignant tumors. ..
  4. Langer R, Ott K, Feith M, Lordick F, Siewert J, Becker K. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Mod Pathol. 2009;22:1555-63 pubmed publisher
    ..Therefore, we strongly recommend the implementation of a standardized tumor regression grading system in pathological reports of esophageal adenocarcinomas treated by neoadjuvant chemotherapy. ..
  5. Langer R, Geissinger E, Rudiger T, von Schilling C, Ott G, Mandl Weber S, et al. Peripheral T-cell lymphoma with progression to a clonally related, Epstein Barr virus+, cytotoxic aggressive T-cell lymphoma: evidence for secondary EBV infection of an established malignant T-cell clone. Am J Surg Pathol. 2010;34:1382-7 pubmed publisher
    ..This case shows that secondary EBV infection of an established malignant T-cell clone can occur and may contribute to aggressive transformation of PTCL...
  6. Langer R, Rauser S, Feith M, Nährig J, Feuchtinger A, Friess H, et al. Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. Mod Pathol. 2011;24:908-16 pubmed publisher
    ..Assessment of ErbB2 amplification can be equivalently performed by conventional fluorescence in situ hybridisation or other light-microscopy-based methods, such as the novel bright field double in situ hybridisation technique. ..